About this Research Topic
Close to 463 million adults are currently living with diabetes and a rise to 700 million is predicted by 2045. Multiple complications associated with diabetes have been identified and described thus far. Both type 1 and type 2 diabetes (T1D and T2D) constitute a major source of morbidity and mortality with macrovascular (coronary artery disease, peripheral arterial disease, and stroke) and microvascular (diabetic nephropathy, neuropathy, and retinopathy) complications, with T2D being the most prevalent (around 90%). Apart from these complications, the importance of T2D in the development and progression of other pathologies, such as Non-Alcoholic Fatty Liver Disease (NAFLD), has been also reported. Although some of the newer anti-hyperglycemic medications such as the sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon like peptide-1 receptor agonist (GLP-1 RA), endothelin A receptor blockade and anti-inflammatory drugs, have been demonstrated to have preclinical and clinical efficacy when it comes to the progression of DM complications, the underlying mechanisms of diabetes-associated damage in target tissues have not been fully understood yet.
The main aim of this Research Topic is to further increase the knowledge behind the mechanisms underlying diabetic related damage in target tissues such as kidney, vessels, liver, fat, muscle and heart. Although numerous mechanisms in this field have been elucidated over the past decades, some unanswered questions still remain in terms of improving the actual treatments being used to address this pathology. In addition, another goal of this topic is to summarize, discuss and contrast the current state of the art and scientific evidence behind the widely variable experimental designs and validated preclinical models that reliably recreate the effects observed in diabetes related complications. Altogether, this topic could improve the comprehension of the pathophysiological mechanisms, the possible effects of novel therapies based on metabolic control as well as their respective protective actions on target-organs. This Research Topic strives to provide a better understanding of the anti-hyperglycemic drugs, while at the same time contributing to the development of new therapeutic strategies.
We invite authors to submit any work focused on investigating new mechanisms implicated in the pathophysiology of diabetic-related diseases. Also, research on potential biomarkers and/or therapeutic targets focusing on prevent or reduce diabetic-associated pathologies are welcome. This special topic is open to Original Research Articles, Reviews or Mini-Reviews exposing a critical point of view or Brief Research Reports contrasting preliminary evidence and discussing a new hypothesis, theory and perspective that brings another perspective concerning the pathophysiological mechanism of progression related with tissue-specific manifestations of diabetes.
Some relevant topics include:
• New therapeutic targets in tissue-specific manifestations of diabetes (retinopathy, cardiomyopathy, nephropathy, neuropathy, non-alcoholic fatty liver disease, among others).
• Evolution of regulatory microRNA in tissue-specific manifestations of diabetes
• Inflammatory pathways involved in the progression of micro and macrovascular diabetic complications.
• Protective and deleterious effects of new anti-hyperglycemic drugs in diabetic and non-diabetic preclinical models.
The Topic Editors would like to acknowledge Dr. Lucas Opazo Ríos for his collaboration in the organization of this Research Topic.
The main aim of this Research Topic is to further increase the knowledge behind the mechanisms underlying diabetic related damage in target tissues such as kidney, vessels, liver, fat, muscle and heart. Although numerous mechanisms in this field have been elucidated over the past decades, some unanswered questions still remain in terms of improving the actual treatments being used to address this pathology. In addition, another goal of this topic is to summarize, discuss and contrast the current state of the art and scientific evidence behind the widely variable experimental designs and validated preclinical models that reliably recreate the effects observed in diabetes related complications. Altogether, this topic could improve the comprehension of the pathophysiological mechanisms, the possible effects of novel therapies based on metabolic control as well as their respective protective actions on target-organs. This Research Topic strives to provide a better understanding of the anti-hyperglycemic drugs, while at the same time contributing to the development of new therapeutic strategies.
We invite authors to submit any work focused on investigating new mechanisms implicated in the pathophysiology of diabetic-related diseases. Also, research on potential biomarkers and/or therapeutic targets focusing on prevent or reduce diabetic-associated pathologies are welcome. This special topic is open to Original Research Articles, Reviews or Mini-Reviews exposing a critical point of view or Brief Research Reports contrasting preliminary evidence and discussing a new hypothesis, theory and perspective that brings another perspective concerning the pathophysiological mechanism of progression related with tissue-specific manifestations of diabetes.
Some relevant topics include:
• New therapeutic targets in tissue-specific manifestations of diabetes (retinopathy, cardiomyopathy, nephropathy, neuropathy, non-alcoholic fatty liver disease, among others).
• Evolution of regulatory microRNA in tissue-specific manifestations of diabetes
• Inflammatory pathways involved in the progression of micro and macrovascular diabetic complications.
• Protective and deleterious effects of new anti-hyperglycemic drugs in diabetic and non-diabetic preclinical models.
The Topic Editors would like to acknowledge Dr. Lucas Opazo Ríos for his collaboration in the organization of this Research Topic.
Keywords: Diabetes, Inflammation, Fibrosis, Obesity, Lipotoxicity
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
